Optimal dialysis for the end-stage renal disease patient with cardiovascular disease

Advances in Chronic Kidney Disease

Volumn 11, Issue 3, 2004, Pages 261-273

  Dumler, Francis ^a,b   McCullough, Peter A ^a  

^a Department of Medicine   (United States)

^b Suite 644 48073   (United States)

Author keywords

anemia; arrhythmias; cardiovascular disease; dialysis hypotension; Dialyzer reactions; ischemia

Indexed keywords

ACETIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARNITINE; CARVEDILOL; CLONIDINE; CUPROPHANE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; MIDODRINE; MINOXIDIL; NIFEDIPINE; OXYGEN; PARACETAMOL; POLYACRYLONITRILE; POTASSIUM; RECOMBINANT ERYTHROPOIETIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VASOCONSTRICTOR AGENT;

ANAPHYLACTIC SHOCK; ANEMIA; ARTIFICIAL KIDNEY; AUTONOMIC DYSFUNCTION; BACKACHE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIALYSIS; DISEASE CLASSIFICATION; DYSPNEA; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HEMODYNAMICS; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXEMIA; IATROGENIC DISEASE; KIDNEY FAILURE; LEUKOPENIA; MUSCLE NECROSIS; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOFT TISSUE CALCIFICATION; SYMPTOM; THORAX DISEASE;

EID: 3242715995     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.arrt.2004.04.004     Document Type: Article

References (123)

1. McCullough P.A. Acute coronary syndromes in patients with renal failure. Curr Cardiol Rep. 5:2003;266-270
2. Collins A.J. Cardiovascular mortality in end-stage renal disease. Am J Med Sci. 4:2003;163-167
3. Foley R.N. Clinical epidemiology of cardiac disease in dialysis patients Left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial. 16:2003;111-117
4. Kendrick E. CVD and the renal transplant recipient. Am J Kidney Dis. 38:(suppl):2001;S36-S43
5. Collins A.J., Li S., Ma J.Z., et al. CVD in end-stage renal disease patients. Am J Kidney Dis. 38:(suppl):2001;S26-S29
6. Amann K., Tyralla K., Gross M.L., et al. Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol. 60:(suppl):2003;S13-S21
7. Zoccali C., Mallamaci F., Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int. 85:(suppl):2003;S105-S110
8. Prichard S. Risk factors for coronary artery disease in patients with renal failure. Am J Med Sci. 325:2003;309-313
9. Reslerova M., Moe S.M. Vascular calcification in dialysis patients Pathogenesis and consequences. Am J Kidney Dis. 41:(suppl):2003;S96-S99
10. Paparello J., Kshirsagar A., Batlle D. Comorbidity and cardiovascular risk factors in patients with CKD. Semin Nephrol. 22:2002;. 494-450
11. Ponticelli C., Villa M. Role of anaemia in cardiovascular mortality and morbidity in transplant patients. Nephrol Dial Transplant. 17:2002;41-46
12. Salusky I.B., Goodman W.G. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant. 17:2002;336-339
13. Bayes B., Pastor M.C., Bonal J., et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant. 18:2003;6-12
14. De Santo N.G., Cirillo M., Perna A., et al. The heart in uremia Role of hypertension, hypotension, and sleep apnea. Am J Kidney Dis. 38:(suppl):2001;S38-S46
15. U.S. Renal Data System: USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. 2003;National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
16. Caruana R.J. First-use reactions A potential hazard for referral centers. Int J Artif Organs. 12:(11):1989;688-691
17. Daugirdas J.T., Ing T.S. First-use reactions during hemodialysis A definition of subtypes. Kidney Int. 24:(suppl):1988;S37-S43
18. Lemke H.D., Heidland A., Schaefer R.M. Hypersensitivity reactions during haemodialysis Role of complement fragments and ethylene oxide antibodies. Nephrol Dial Transplant. 5:1990;264-269
19. Nicholls A.J. Hypersensitivity to hemodialysis The United Kingdom experience. Artif Organs. 11:1987;87-89
20. Bommer J., Ritz E. Ethylene oxide (ETO) as a major cause of anaphylactoid reactions in dialysis (a review). Artif Organs. 11:1987;111-117
21. Hakim R.M., Breillatt J., Lazarus J.M., et al. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med. 311:1984;878-882
22. Schulman G., Hakim R., Arias R., et al. Bradykinin generation by dialysis membranes Possible role in anaphylactic reaction. J Am Soc Nephrol. 3:1993;1563-1569
23. Pegues D.A., Beck-Sague C.M., Woollen S.W., et al. Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Int. 42:1992;1232-1237
24. Brunet P., Jaber K., Berland Y., et al. Anaphylactoid reactions during hemodialysis and hemofiltration Role of associating AN69 membrane and angiotensin I-converting enzyme inhibitors. Am J Kidney Dis. 19:1992;444-447
25. Parnes E.L., Shapiro W.B. Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney Int. 40:1991;1148-1152
26. Tielemans C., Madhoun P., Lenaers M. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int. 38:1990;982-984
27. Wiegmann T.B., MacDougall M.L., Diederich D.A. Dialysis leukopenia, hypoxemia, and anaphylatoxin formation Effect of membrane, bath, and citrate anticoagulation. Am J Kidney Dis. 11:1988;418-424
28. Abu-Hamdan D.K., Desai S.G., Mahajan S.K., et al. Hypoxemia during hemodialysis using acetate versus bicarbonate dialysate. Am J Nephrol. 4:1984;248-253
29. Hakim R.M., Lowrie E.G. Hemodialysis-associated neutropenia and hypoxemia The effect of dialyzer membrane materials. Nephron. 32:1982;32-39
30. Dumler F. Membrane biocompatibility Clinical significance and therapeutic implications. Int J Artif Organs. 8:1985;257-262
31. Daugirdas J.T. Pathophysiology of dialysis hypotension An update. Am J Kidney Dis. 38:(suppl):2001;S11-S17
32. Barth C., Boer W., Garzoni D., et al. Characteristics of hypotension-prone haemodialysis patients Is there a critical relative blood volume? Nephrol Dial Transplant. 18:2003;353-360
33. Andrulli S., Colzani S., Mascia F., et al. The role of blood volume reduction in the genesis of intradialytic hypotension. Am J Kidney Dis. 40:2002;1244-1254
34. Prakash S., Reddan D., Heidenheim A.P., et al. Central, peripheral, and other blood volume changes during hemodialysis. ASAIO J. 48:2002;379-382
35. Sherman R.A. Intradialytic hypotension An overview of recent, unresolved and overlooked issues. Semin Dial. 15:2002;141-143
36. Leypoldt J.K., Cheung A.K., Delmez J.A. Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int. 61:2002;266-275
37. Bradley J.R., Evans D.B., Gore S.M., et al. Is dialysis hypotension caused by an abnormality of venous tone? Br Med J. 296:1988;1634-1637
38. Kooman J.P., Gladziwa U., Bocker G., et al. Role of the venous system in hemodynamics during ultrafiltration and bicarbonate dialysis. Kidney Int. 42:1992;718-726
39. Chang M.H., Chou K.J. The role of autonomic neuropathy in the genesis of intradialytic hypotension. Am J Nephrol. 21:2001;357-361
40. Henrich W.L. Hemodynamic instability during hemodialysis. Kidney Int. 30:1986;605
41. Converse R.L. Jr, Jacobsen T.N., Jost C.M., et al. Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest. 90:1992;1657-1665
42. Zhu F., Schneditz D., Wang E., et al. Validation of changes in extracellular volume measured during hemodialysis using a segmental bioimpedance technique. ASAIO J. 44:1998;541-545
43. Dumler F., Kilates C. Use of bioelectrical impedance techniques for monitoring nutritional status in patients on maintenance dialysis. J Ren Nutr. 10:2000;116-124
44. Cox-Reijven P.L., Kooman J.P., Soeters P.B., et al. Role of bioimpedance spectroscopy in assessment of body water compartments in hemodialysis patients. Am J Kidney Dis. 38:2001;832-838
45. Kushner R.F., Roxe D.M. Bipedal bioelectrical impedance analysis reproducibly estimates total body water in hemodialysis patients. Am J Kidney Dis. 39:2002;154-158
46. Chamney P.W., Kramer M., Rode C., et al. A new technique for establishing dry weight in hemodialysis patients via whole body bioimpedance. Kidney Int. 6:2002;12250-12258
47. Konings C.J., Kooman J.P., Schonck M., et al. Assessment of fluid status in peritoneal dialysis patients. Perit Dial Int. 22:2002;683-692
48. Zhu F., Schneditz D., Kaufman A.M., et al. Estimation of body fluid changes during peritoneal dialysis by segmental bioimpedance analysis. Kidney Int. 57:2000;299-306
49. Piccoli A., Rossi B., Pillon L., et al. A new method for monitoring body fluid variation by bioimpedance analysis The RXc graph. Kidney Int. 46:1994;534-539
50. Piccoli A., Pillon L., Dumler F. Impedance vector distribution by sex, race, body mass index, and age in the United States Standard reference intervals as bivariate Z scores. Nutrition. 18:2002;153-167
51. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 347:2002;161-167
52. Vesely D.L. Natriuretic peptides and acute renal failure. Am J Physiol Renal Physiol. 285:2003;F167-F177
53. Kanozawa K., Shimosawa T., Nagasawa R., et al. Mature form of adrenomedullin is a useful marker to evaluate blood volume in hemodialysis patients. Am J Kidney Dis. 40:2002;794-801
54. Cataliotti A., Malatino L.S., Jougasaki M., et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease Role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc. 76:2001;1111-1119
55. Metry G., Hall C., Wikstrom B., et al. Fluid balance in patients with chronic renal failure assessed with N-terminal proatrial natriuretic peptide, atrial natriuretic peptide and ultrasonography. Acta Physiol Scand. 171:2001;117-122
56. Franz M., Woloszczuk W., Horl W.H. N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int. 58:2000;374-383
57. Odar-Cederlof I., Ericsson F., Theodorsson E., et al. Neuropeptide-Y and atrial natriuretic peptide as prognostic markers in patients on hemodialysis. ASAIO J. 49:2003;74-80
58. Zoccali C., Mallamaci F., Benedetto F.A., et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 12:2001;1508-1515
59. Nishikimi T., Futoo Y., Tamano K., et al. Plasma brain natriuretic peptide levels in chronic hemodialysis patients Influence of coronary artery disease. Am J Kidney Dis. 37:2001;201-208
60. Mallamaci F., Zoccali C., Tripepi G., et al. The Cardiovascular Risk Extended Evaluation. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 59:2001;1559-1566
61. McIntyre C.W., Lambie S.H., Fluck R.J. Biofeedback controlled hemodialysis (BF-HD) reduces symptoms and increases both hemodynamic tolerability and dialysis adequacy in non-hypotensive prone stable patients. Clin Nephrol. 60:2003;105-112
62. Santoro A., Mancini E., Basile C., et al. Blood volume controlled hemodialysis in hypotensive-prone patients A randomized, multicenter, controlled trial. Kidney Int. 62:2002;1043-1045
63. Song J.H., Lee S.W., Suh C.K., et al. Time-averaged concentration of dialysate sodium relates with sodium load and interdialytic weight gain during sodium-profiling hemodialysis. AM J Kidney Dis. 40:2002;291-301
64. Monger M.A., Ateshkadi A., Cheung A.K., et al. Cardiopulmonary events during hemodialysis Effects of dialysis membranes and dialysate buffers. Am J Kidney Dis. 36:2000;130-139
65. Verzetti G., Navino C., Bolzani R., et al. Acetate-free biofiltration versus bicarbonate haemodialysis in the treatment of patients with diabetic nephropathy A cross-over multicentric study. Nephrol Dial Transplant. 13:1998;955-961
66. Donauer J., Schweiger C., Rumberger B., et al. Reduction of hypotensive effects during online-haemodiafiltration and low tempaerature haemodialysis. Nephrol Dial Transplant. 18:2003;1616-1622
67. Hoeben H., Abu-Alfa A.K., Mahnensmith R. Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine. Am J kidney Dis. 39:2002;102-107
68. Berger A.K., Duval S., Krumholz H.M. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 42:2003;201-208
69. Cice G., Ferrara L., D'Andrea A., et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy a prospective, placebo-controlled trial. J Am Coll Cardiol. 41:2003;1438-1444
70. Alappan R., Cruz D., Abu-Alfa A.K., et al. Treatment of severe intradialytic hypotension with the addition of high dialysate calcium concentration to midodrine and/or cool dialysate. Am J Kidney Dis. 37:2001;294
71. Levin A. Anemia and left ventricular hypertrophy in CKD populations A review of the current state of knowledge. Kidney Int. 80:(suppl):2002;35-38
72. Stack A.G., Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis. 406:2002;1202-1210
73. Gomez J.M., Carrera F. What should the optimal target hemoglobin be? Kidney Int. 80:(suppl):2002;39-43
74. Ahmad S., Robertson H.T., Golper T.A., et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int. 38:(5):1990;912-918
75. Emili S., Black N.A., Paul R.V., et al. A protocol-based treatment for intradialytic hypotension in hospitalized hemodialysis patients. Am J kidney Dis. 33:1999;1107-1114
76. Cruz D.N., Mahnensmith R.L., Brickel H.M., et al. Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. Am J Kidney Dis. 33:1999;920-926
77. Donauer J., Kolblin D., Bek M., et al. Ultrafiltration profiling and measurement of relative blood volume as strategies to reduce hemodialysis-related side effects. Am J Kidney Dis. 36:2000;115-123
78. Dheenan S., Heinrich W.L. Preventing dialysis hypotension A comparison of usual protective maneuvers. Kidney Int. 59:2001;1175-1181
79. Stiller S., Bonnie-Schorn E., Grassmann A., et al. A critical review of sodium profiling for hemodialysis. Semin Dial. 14:2001;337-347
80. Perazella M.A. Pharmacologic options available to treat symptomatic intradialytic hypotension. Am J Kidney Dis. 38:(suppl):2001;S26-S36
81. Nette R.W., Krepel H.P., van den Meiracker A.H., et al. Specific effect of the infusion of glucose on blood volume during haemodialysis. Nephrol Dial Transplant. 17:2002;1275-1280
82. Begin V., Deziel C., Madore F. Biofeedback regulation of ultrafiltration and dialysate conductivity for the prevention of hypotension during hemodialysis. ASAIO J. 48:2002;312-315
83. Bellinghieri G., Santoro D., Calvini M., et al. Carnitine and hemodialysis. Am J Kidney Dis. 41:(suppl):2003;S111-S122
84. Nakamura S., Uzu T., Inenaga T., et al. Prediction of coronary artery disease and cardiac events using electrocardiographic changes during hemodialysis. Am J Kidney Dis. 36:(3):2000;592-599
85. Freda B.J., Tang W.H., Van Lente F., et al. Cardiac troponins in renal insufficiency Review and clinical implications. J Am Coll Cardiol. 40:(12):2002;2065-2071
86. McCullough P.A., Nowak R.M., Foreback C., et al. Performance of multiple cardiac biomarkers measured in the emergency department in patients with chronic kidney disease and chest pain. Acad Emerg Med. 9:2002;1389-1396
87. Apple F.S., Murakami M.M., Pearce L.A., et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 106:(23):2002;2941-2945
88. Jassal S.B.V., Coulshed S.J., Douglas J.F., et al. Autonomic neuropathy predisposing to arrhythmias in hemodialysis patients. Am J Kidney Dis. 30:1997;219-223
89. Bleyer A.J., Russell G.B., Satko S.G. Sudden and cardiac death rates in hemodialysis patients. Kidney Int. 55:1999;1553-1559
90. Barnas M.G., Boer W.H., Koomans H.A. Hemodynamic patterns and spectral analysis of heart rate variability during dialysis hypotension. J Am Soc Nephrol. 10:1999;2577-2584
91. Vazquez E., Sanchez-Perales C., Lozano C., et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol. 92:2003;868-871
92. Herzog C.A. Cardiac arrest in dialysis patients Approaches to alter an abysmal outcome. Kidney Int. 84:(suppl):2003;S197-S200
93. Eknoyan G., Beck G.J., Cheung A.K., et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 347:2002;2010-2019
94. Rahman M., Dixit A., Donley V., et al. Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis. 33:1999;498-506
95. Sang G.L., Kovithavongs C., Ulan R., et al. Sodium ramping in hemodialysis A study of beneficial and adverse effects. Am J Kidney Dis. 29:1997;669-677
96. Dumler F., Levin N.W. Leukopenia and hypoxemia Unrelated effects of hemodialysis. Arch Intern Med. 139:1979;1103-1106
97. Hakim R.M., Lowrie E.G. Hemodialysis-associated neutropenia and hypoxemia The effect of dialyzer membrane materials. Nephron. 32:1982;32-39
98. Abu-Hamdan D.K., Desai S.G., Mahajan S.K., et al. Hypoxemia during hemodialysis using acetate versus bicarbonate dialysate. Am J Nephrol. 4:1984;248-253
99. Francos G.C., Besarab A., Burke F., et al. Dialysis-induced hypoxemia Membrane dependent and membrane independent causes. Am J Kidney Dis. 5:1985;191-198
100. 2 in metabolism of acetate. Am J Nephrol. 5:1985;366-371
101. Ross E.A., Tashkin D., Chenoweth D., et al. Pulmonary leukosequestration without hypoxemia during hemodialysis. Int J Artif Organs. 10:1987;367-374
102. Wiegmann T.B., MacDougall M.L., Diederich D.A. Dialysis leukopenia, hypoxemia, and anaphylatoxin formation effect of membrane, bath, and citrate anticoagulation. Am J Kidney Dis. 11:1988;418-424
103. Soliani F., Davoli V., Franco V., et al. Intradialytic changes of the oxyhaemoglobin dissociation curve during acetate and bicarbonate haemodialysis Possible interactions with haemodialysis associated hypoxemia. Nephrol Dial Transplant. 5:(suppl 1):1990;119-121
104. Ganss R., Aarseth B.P., Nordby G. Prevention of hemodialysis associated hypoxemia by use of low concentration bicarbonate dialysate. ASAIO J. 38:1992;820-822
105. Wang A.Y., Woo J., Wang M., et al. Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol. 12:2001;1927-1936
106. Pecoits-Filho R., Lindholm B., Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant. 17:(suppl 11):2002;28-31
107. Raggi P., Ali O. Phosphorus restriction and control of coronary calcification as assessed by electron beam tomography. Curr Opin Nephrol Hypertens. 11:2002;391-395
108. Raggi P. Effects of excess calcium load on the cardiovascular system measured by electron beam tomography in end-stage renal disease. Nephrol Dial Transplant. 17:2002;332-335
109. Raggi P., Boulay A., Chasan-Taber S., et al. Cardiac calcification in adult hemodialysis patients A link between end-stage renal disease and CVD? J Am Coll Cardiol. 39:2002;695-701
110. Wang A.Y., Wang M., Woo J., et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients A prospective study. J Am Soc Nephrol. 14:2003;159-168
111. Di Leo C., Gallieni M., Bestetti A., et al. Cardiac and pulmonary calcification in a hemodialysis patient partial regression 4 years after parathyroidectomy. Clin Nephrol. 59:2003;59-63
112. Ummana E., Ahmed W., Alpert M.A. Valvular and perivalvular abnormalities in end-stage renal disease. Am J Med Sci. 325:2003;237-242
113. Chertow G.M., Raggi P., McCarthy J.T., et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol. 2:2003;307-314
114. Raggi P., Bommer J., Chertow G.M. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis. 13:2004;134-141
115. McCullough PA, Sandberg KR, Yanez J: Determinants of vascular calcification in patients with chronic kidney disease and end-stage renal disease: A systematic review. J Nephrol (in press)
116. Chan C.T., Floras J.S., Miller J.A., et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 61:2002;2235-2239
117. Klarenbach S., Heidenheim A.P., Leitch R., et al. Daily/Nocturnal Dialysis Study Group. Reduced requirement for erythropoietin with quotidian hemodialysis therapy. ASAIO J. 48:2002;57-61
118. Chan C., Floras J.S., Miller J.A., et al. Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant. 17:2002;1518-1521
119. Andre M.B., Rembold S.M., Pereira C.M., et al. Prospective evaluation of an in-center daily hemodialysis program Results of two years of treatment. Am J Nephrol. 22:2002;473-479
120. Lindsay R.M., Alhejaili F., Nesrallah G., et al. Calcium and phosphate balance with quotidian hemodialysis. Am J Kidney Dis. 42:(1 suppl):2003;24-29
121. Chan C.T., Mardirossian S., Faratro R., et al. Improvement in lower-extremity peripheral arterial disease by nocturnal hemodialysis. Am J Kidney Dis. 4:2003;225-229
122. Ganesh S.K., Hulbert-Shearon T., Port F.K., et al. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol. 14:2003;415-424
123. United States Renal Data System: USRDS 2003 Annual Data Report. US Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis. 41:(suppl 2):2003;S1-S226